Pharmacoeconomics
On this page
Direct answer
Choosing between two equally effective antihypertensives is not a clinical question but an economic one — cost-minimisation analysis, the first of four pharmacoeconomic tools. The family: cost-minimisation analysis (outcomes proven equivalent, compare raw costs); cost-effectiveness analysis (a clinical unit — cost per mmHg, per stroke prevented, as an incremental cost-effectiveness ratio); cost-utility analysis (cost per quality-adjusted life year); and cost-benefit analysis (everything in rupees). Costs layer into direct medical, direct non-medical, indirect and intangible. The Indian frame is concrete: out-of-pocket payments still account for roughly half of total health expenditure, catastrophic spending pushes families below the poverty line, and instruments like the NLEM, DPCO ceilings by NPPA, Jan Aushadhi stores and PM-JAY exist to bend these curves.
What you must remember
- Four analyses and their denominators: CMA — rupees only (outcomes identical by evidence); CEA — rupees per clinical event or unit (mmHg, relapse prevented); CUA — rupees per QALY; CBA — everything in rupees, net monetary benefit.
- ICER arithmetic: (cost of new drug − cost of comparator) ÷ (effect of new drug − effect of comparator); an ICER below the willingness-to-pay threshold marks the drug cost-effective.
- QALY construction: one year of perfect health = 1.0; one year at utility 0.5 = 0.5 QALY; utilities come from instruments like EQ-5D — and critics note they penalise disability and age.
- Threshold conventions: NICE in the UK uses roughly 20,000-30,000 pounds per QALY; WHO-CHOICE logic classifies interventions as highly cost-effective below a country's per-capita GDP per DALY averted — the figure Indian health-technology assessments borrow.
- Perspective matters: a cheap drug shifted to home administration saves the hospital money and loads indirect costs onto the patient — the societal perspective captures both.
- Discounting and sensitivity analysis: future costs and benefits are discounted (commonly 3-5 percent annually); sensitivity analysis stress-tests the conclusion against uncertain inputs.
- Indian cost-control machinery: NLEM inclusion triggers DPCO 2013 price caps by NPPA; Pradhan Mantri Bhartiya Janaushadhi Pariyojana outlets sell quality-assured generics at deep discounts; PM-JAY covers hospitalisation for the bottom two-fifths economically.
- Prescriber-level rule: for equivalent outcomes (bioequivalent generics, therapeutic equivalents), the cheapest option is the rational option — the ethics of the prescription pad.
Working an ICER through an Indian example
Suppose a new oral anticoagulant costs 40,000 rupees a year against warfarin at 4,000, and in a modelled cohort prevents 4 additional strokes per 1,000 patients annually. The incremental cost is 36,000 rupees per patient; the incremental effect, 0.004 strokes prevented per patient; the ICER is 36,000 ÷ 0.004 = 9,000,000 rupees per stroke prevented. Whether that is worth it depends on the system's threshold and on hidden variables the model must price: INR monitoring visits for warfarin (transport, half-day wages — the indirect costs), intracranial haemorrhage rates, and adherence. Repeating the exercise as cost-utility converts strokes and bleeds into QALYs, discounts future benefits at 3 percent, and stress-tests the haemorrhage rate through sensitivity analysis. This is the reasoning Indian health-technology assessment bodies apply — with scarce Indian cost data, but explicitly. The moral: a drug can be effective, safe and still unaffordable at population scale — pharmacoeconomics is where efficacy meets the budget.
Where students slip
The classic error is using cost-minimisation when outcomes merely "seem" similar — CMA is legitimate only when equivalence has been demonstrated, not assumed; otherwise the analysis silently discards the effectiveness difference. The second slip is reporting an average cost ("the drug costs X per patient") where the exam asked for an incremental ratio — ICERs compare differences to differences. Third, candidates forget the perspective line: from the patient's perspective a day in hospital includes lost daily wages, which the hospital's ledger never shows; Indian out-of-pocket catastrophic spending is precisely a perspective failure at the level of national policy.
Frequently asked questions
When is cost-minimisation analysis the appropriate method?
Only when two therapies have been shown to produce equivalent outcomes, so the comparison reduces to total costs alone — assuming equivalence without evidence invalidates it.
What is an ICER and how is it interpreted?
The incremental cost-effectiveness ratio — the extra cost divided by the extra effect of one therapy over another; it is judged against a willingness-to-pay threshold such as cost per QALY limits used by bodies like NICE.
What is a QALY and why is it useful?
A quality-adjusted life year multiplies years of survival by a utility weight between 0 and 1, letting very different interventions — dialysis, vaccination, palliative care — be compared on one scale.
How do Indian mechanisms reduce drug costs at population level?
NLEM listing brings drugs under DPCO price ceilings fixed by NPPA, Jan Aushadhi stores dispense low-cost quality generics, and PM-JAY shields poor households from hospitalisation expenses.
What are indirect costs in a pharmacoeconomic evaluation?
Productivity losses — wages forfeited, time spent travelling and waiting, unpaid caregiver time — invisible in the hospital ledger but central to the societal perspective.